Drug intelligence / Profile preview

GLS-6100

Development stage: Preclinical
Lead developer: GeneOne Life Science
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

GLS-6100 is a prophylactic DNA vaccine candidate being developed by GeneOne Life Science for the prevention of hepatitis C virus (HCV) infection. The vaccine is designed as a biological modality to provide an efficacious, safe, and cost-effective means to prevent HCV infection in at-risk individuals who have never been exposed to the virus. GLS-6100 works by delivering DNA plasmids that encode multiple HCV proteins into host cells, where they are expressed to elicit a broad and robust immune response intended to prevent viral growth and establishment of infection upon exposure.

Beyond the preview

Go deeper on GLS-6100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLS-6100.

Explore the full profile